Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapy entities : Bristol-myers squibb company save search
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Published: 2024-04-05 (Crawled : 14:00) - biospace.com/
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: 7.98%
H: 9.06%
C: -9.06%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.41%
H: 0.51%
C: 0.25%
fda for therapy
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
Published: 2024-03-15 (Crawled : 23:00) - biospace.com/
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: 2.27%
H: 8.4%
C: -0.99%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.32%
H: 1.67%
C: 0.04%
fda therapy
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $65.26 -4.38% 5.9K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
Published: 2024-01-26 (Crawled : 15:30) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.71%
H: 0.48%
C: -0.52%
chmp positive cell therapy
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
Published: 2023-12-12 (Crawled : 08:00) - biospace.com/
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: -4.02%
H: 9.35%
C: 4.84%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.57%
H: 0.28%
C: -0.57%
therapy
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Published: 2023-11-20 (Crawled : 13:00) - biospace.com/
TSVT | $4.28 -7.56% -8.18% 470K
|
|
| O: -11.74%
H: 1.06%
C: -7.45%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -4.05%
H: 2.85%
C: 0.25%
fda review update therapy
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
Published: 2023-08-28 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.03%
H: 0.56%
C: -0.68%
partnership cell car-t program technology therapy platform
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
Published: 2023-06-08 (Crawled : 22:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.28%
H: 0.42%
C: -0.05%
fda approval cell therapy
Global HIV Treatment Market Report 2023: Advances in Gene Therapy Present Significant Opportunities for Sector Growth
Published: 2023-05-31 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -0.24%
H: 2.1%
C: 2.1%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: 0.33%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.42%
H: 0.83%
C: -0.41%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.34%
H: 0.32%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.24%
H: 1.43%
C: 0.84%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.03%
H: 0.41%
C: 0.34%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: -1.35%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.09%
H: 0.97%
C: 0.89%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -1.72%
report treatment global hiv therapy growth market
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
Published: 2023-05-03 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.34%
H: 0.6%
C: -2.47%
breyanzi approval one cell therapy
Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production
Published: 2023-04-26 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: -0.91%
H: 0.2%
C: -2.27%
cell therapy
Breast Cancer Therapeutics Market Research Report 2023: Therapy, Chemotherapy Drugs, Hormone Therapy, Targeted Therapy - Global Forecasts to 2027
Published: 2023-03-04 (Crawled : 04:20) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
| Email alert
Add to watchlist
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
| Email alert
Add to watchlist
research global report breast therapeutics therapy cancer market hormone
CAR-T Cell Therapy Market Size to Reach USD 9.62 Million in 2030| Emergen Research
Published: 2023-01-09 (Crawled : 16:00) - prnewswire.com
ALPMF | News | $9.5 43.47% 1.2K
|
Health Technology
|
| O: 3.03%
H: 0.0%
C: 0.0%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 3.12%
H: 0.0%
C: -2.55%
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: 0.58%
H: 0.44%
C: -0.31%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.76%
H: 0.26%
C: -3.27%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.29%
H: 0.27%
C: -3.89%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.16%
H: 0.05%
C: -2.89%
BNTX | News | $88.18 -0.35% -0.35% 280K
|
Health Technology
|
| O: 1.42%
H: 0.64%
C: -2.27%
research car-t therapy market
Cancer Gene Therapy Market to Reach $8.7 Billion By 2030 at a CAGR of 19.99%
Published: 2022-11-24 (Crawled : 21:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.21%
H: 0.59%
C: -0.09%
ABEO | News | $3.165 -7.19% -7.74% 2.2M
|
Health Technology
|
| O: -0.76%
H: 2.05%
C: -0.26%
therapy cancer market
U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for CAMZYOS® (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy to Reduce the Need for Septal Reduction Therapy
Published: 2022-10-21 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.0%
H: 3.08%
C: 2.64%
camzyos drug application food therapy
Arsenal Biosciences Closes $220 Million Series B Financing to Advance Programmable Cell Therapy Programs into Clinical Development
Published: 2022-09-06 (Crawled : 14:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.48%
H: 0.19%
C: -0.42%
therapy
Global Cell and Gene Therapy Market to Surpass US$ 90,984.2 Million by 2030 - Coherent Market Insights
Published: 2022-08-24 (Crawled : 18:00) - prnewswire.com
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.33%
H: 0.16%
C: -0.81%
BMRN | $91.25 -0.88% -0.89% 1.6M
|
Health Technology
|
| O: -0.04%
H: 2.33%
C: 1.47%
global therapy market
Global Engineered T Cells Market Report 2022-2027: Immuno-Oncology Sector Increasing R&D Funding & Expanding Gene Therapy Marketspace Generating High-Potential Opportunities
Published: 2022-08-12 (Crawled : 14:20) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 1.51%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.61%
H: 0.9%
C: 0.73%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.16%
H: 1.53%
C: 1.33%
DTIL | $9.81 -4.11% -4.28% 34K
|
Health Technology
|
| O: 0.61%
H: 23.78%
C: 22.56%
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: -1.7%
H: 12.62%
C: 8.91%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.42%
H: 0.45%
C: 0.4%
CABA | $12.94 -2.85% -2.94% 930K
|
Health Technology
|
| O: 2.76%
H: 4.7%
C: 2.68%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 3.58%
H: 1.99%
C: -1.41%
ATNX | $0.2031 -7.78% 1.9M
|
Health Technology
|
| O: 2.25%
H: 0.0%
C: 0.0%
AMGN | News | $273.085 -0.17% -0.17% 2.5M
|
Health Technology
|
| O: 0.07%
H: 0.54%
C: -0.05%
global report funding therapy market
Cancer Immunotherapy Market Expands with Rising Adoption of Target Therapy in Cancer Treatment, States TMR Report
Published: 2022-06-27 (Crawled : 16:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: 0.47%
H: 3.73%
C: 3.73%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 4.15%
H: 0.0%
C: 0.0%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -1.55%
H: 4.43%
C: 0.03%
PFE | News 4 | $26.27 -0.19% -0.15% 23M
|
Health Technology
|
| O: 1.46%
H: 1.45%
C: 0.78%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.86%
H: 1.05%
C: 0.24%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.16%
H: 0.61%
C: 0.18%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.34%
H: 1.72%
C: 0.95%
SPPI | $1.03 -0.97% 0
|
Health Technology
|
| O: 0.0%
H: 2.28%
C: -2.27%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.53%
H: 0.0%
C: 0.0%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: -0.36%
H: 1.22%
C: 0.38%
immunotherapy report therapy cancer market treatment
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi in Relapsed or Refractory Large B-cell Lymphoma After First-Line Therapy
Published: 2022-06-20 (Crawled : 12:00) - biospace.com/
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
| Email alert
Add to watchlist
application therapy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.